secwatch.observer — SEC 8-K summary
======================================

Issuer:     Onconetix, Inc. (ONCO)
CIK:        0001782107
Form:       8-K
Filed at:   2025-07-16T23:59:59+00:00
Accession:  0001213900-25-064469
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Onconetix agrees to reverse merger with Ocuvex; Ocuvex holders to own 90% of combined company
--------------------------------------------------------------------------------

- Onconetix acquires Ocuvex; Ocuvex holders get 90% of combined co, Onconetix holders 10%.
- Post-close board: 7 directors (5 Ocuvex, 2 Onconetix); closing targeted Q4 2025.
- Series C Preferred conversion price reduced to $3.50 effective through July 31, 2025.
- Andrew Oakley elected Lead Independent Director, to receive $36,000/month.
- Nasdaq compliance regained; subject to Mandatory Panel Monitor through July 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782107/000121390025064469/0001213900-25-064469-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782107/000121390025064469/ea0248815-8k_onconetix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-064469

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer